Led by the brightest minds in the industry
ATAI is home to some of the most sought-after executives and scientists in the space. Equipped with a diverse and dedicated team, we are making a concerted effort to redefine mental health paradigms.
Guided by a noble mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our unique operating model
Our approach combines funding, access to accelerative platform technologies, as well as scientific and regulatory expertise with a singular focus on developing more rapid-acting and potentially disease-modifying mental health treatments.
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Slow onset – Up to 3 months or more for SSRIs to take full effect
Trial and error – Remission with first selected SSRI occurs only 30% of the time
Low response rate – Only 50% respond within 8 weeks and 33% become treatment-resistant
High relapse rate – Estimated that 40-60% of patients with SUD return to active addiction
Addiction – 10-15% of benzodiazepine users become addicted
Sexual dysfunction – 55% of patients on SSRIs experience sexual dysfunction
Weight gain – Depending on the drug, patients on SSRIs gain on average 16-24lbs over 12 months
Sleep – SSRIs interfere with sleep architecture, potentially complicating the sleep of depressed patients
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Our portfolio includes a number of assets that have the potential to be developed as first-in-class therapeutics. These are programs which include natural products and their derivatives that have not previously been formally developed as drugs, as well as de novo compounds.
WHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.OUR MODEL
News & Insights
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the…
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the…
Gender Disparities and Mental Health Risk Factors
We’re social creatures: We not only desire interaction with others but actually need it. Contact with others — particularly physical contact —…